Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Karen M. Alexander is active.

Publication


Featured researches published by Karen M. Alexander.


Neuroscience Letters | 1998

Inhibition of adenosine kinase during oxygen-glucose deprivation in rat cortical neuronal cultures

James J. Lynch; Karen M. Alexander; Michael F. Jarvis; Elizabeth A. Kowaluk

Adenosine kinase (AK) inhibitors potentiate the actions of endogenous adenosine (ADO) and ameliorate cerebral ischemic damage in animal models. The present study examined the effects of the AK inhibitor, 5-iodotubercidin (5-IT) in an in vitro model of neuronal ischemia, specifically, combined oxygen-glucose deprivation of rat cortical mixed neuronal-glial cultures. Oxygen-glucose deprivation caused extensive neuronal loss which was accompanied by a marked increase in ADO release into the extracellular medium, was ameliorated by exogenous ADO (10 microM(-1) mM), and was exacerbated by a high concentration of the selective A1 receptor antagonist 8-cyclopentyl-1,3-dimethylxanthine (CPT; 10 microM). 5-IT (1 microM) had no effect on extracellular ADO levels nor on neuronal loss. However, AK activity in these cultures was markedly suppressed during oxygen-glucose deprivation. Taken together, these data demonstrate a marked down-regulation of AK activity during oxygen-glucose deprivation in this in vitro model, providing an endogenous mechanism contributing to the accumulation of extracellular ADO, which exerts neuroprotective effects by activating the ADO A1 receptor.


Bioorganic & Medicinal Chemistry Letters | 2001

Structure-activity studies of 5-substituted pyridopyrimidines as adenosine kinase inhibitors.

Marlon D. Cowart; Chih-Hung Lee; Gregory A. Gfesser; Erol K. Bayburt; Shripad S. Bhagwat; Andrew O. Stewart; Haixia Yu; Kathy L. Kohlhaas; Steve McGaraughty; Carol T. Wismer; Joseph P. Mikusa; Chang Zhu; Karen M. Alexander; Michael F. Jarvis; Elizabeth A. Kowaluk

The synthesis and SAR of a novel series of non-nucleoside pyridopyrimidine inhibitors of the enzyme adenosine kinase (AK) are described. It was found that pyridopyrimidines with a broad range of medium and large non-polar substituents at the 5-position potently inhibited AK activity. A narrower range of analogues was capable of potently inhibiting adenosine phosphorylation in intact cells indicating an enhanced ability of these analogues to penetrate cell membranes. Potent AK inhibitors were found to effectively reduce nociception in animal models of thermal hyperalgesia and persistent pain.


Bioorganic & Medicinal Chemistry Letters | 2003

Adenosine kinase inhibitors: polar 7-substitutent of pyridopyrimidine derivatives improving their locomotor selectivity.

Guo Zhu Zheng; Yue Mao; Chih-Hung Lee; John K. Pratt; John R. Koenig; Richard J. Perner; Marlon D. Cowart; Gregory A. Gfesser; Steve McGaraughty; Katharine L. Chu; Chang Zhu; Haixia Yu; Kathy L. Kohlhaas; Karen M. Alexander; Carol T. Wismer; Joseph P. Mikusa; Michael F. Jarvis; Elizabeth A. Kowaluk; Andrew O. Stewart

We have discovered that polar 7-substituents of pyridopyrimidine derivatives affect not only whole cell AK inhibitory potency, but also selectivity in causing locomotor side effects in vivo animal models. We have identified compound, 1o, which has potent whole cell AK inhibitory potency, analgesic activity and minimal reduction of locomotor activity.


Bioorganic & Medicinal Chemistry Letters | 1996

Synthesis of phosphorus-containing amino acid analogs as inhibitors of nitric oxide synthase

Marlon Cowart; Elizabeth A. Kowaluk; Kathy L. Kohlhaas; Karen M. Alexander; James F. Kerwin

Abstract Two series of α-amino phosphonic and α-amino phosphinic analogs of arginine were prepared and tested as inhibitors of nitric oxide synthase (NOS). Two of the analogs were found to possess inhibitory activity for the neuronal isoform of NOS.


European Journal of Pharmacology | 1999

Pharmacological characterization of recombinant human and rat P2X receptor subtypes

Bruce R. Bianchi; Kevin J. Lynch; Edward Touma; Wende Niforatos; Edward C. Burgard; Karen M. Alexander; Helen S Park; Haixia Yu; Randy E. Metzger; Elizabeth A. Kowaluk; Michael F. Jarvis; Tim van Biesen


Journal of Pharmacology and Experimental Therapeutics | 2000

ABT-702 (4-Amino-5-(3-bromophenyl)-7-(6-morpholinopyridin-3-yl)pyrido[2,3-d]pyrimidine), a Novel Orally Effective Adenosine Kinase Inhibitor with Analgesic and Anti-Inflammatory Properties: I. In Vitro Characterization and Acute Antinociceptive Effects in the Mouse

Michael F. Jarvis; Haixia Yu; Kathy L. Kohlhaas; Karen M. Alexander; Chih-Hung Lee; Mequin Jiang; Shripad S. Bhagwat; Michael T. Williams; Elizabeth A. Kowaluk


Bioorganic & Medicinal Chemistry | 2005

5-(3-Bromophenyl)-7-(6-morpholin-4-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-4-ylamine: structure–activity relationships of 7-substituted heteroaryl analogs as non-nucleoside adenosine kinase inhibitors

Mark A. Matulenko; Chih-Hung Lee; Meiqun Jiang; Robin R. Frey; Marlon D. Cowart; Erol K. Bayburt; Gregory A. Gfesser; Arthur Gomtsyan; Guo Zhu Zheng; Jeffery McKie; Andrew O. Stewart; Haixia Yu; Kathy L. Kohlhaas; Karen M. Alexander; Steve McGaraughty; Carol T. Wismer; Joseph P. Mikusa; Kennan C. Marsh; Ronald D. Snyder; Marilyn S. Diehl; Elizabeth A. Kowaluk; Michael F. Jarvis; Shripad S. Bhagwat


Journal of Pharmacology and Experimental Therapeutics | 1999

Allosteric Modulation and Accelerated Resensitization of Human P2X3 Receptors by Cibacron Blue

Karen M. Alexander; Wende Niforatos; Bruce R. Bianchi; Edward C. Burgard; Kevin J. Lynch; Elizabeth A. Kowaluk; Michael F. Jarvis; Tim van Biesen


Journal of Medicinal Chemistry | 2003

5,6,7-trisubstituted 4-aminopyrido[2,3-d]pyrimidines as novel inhibitors of adenosine kinase.

Richard J. Perner; Yu-Gui Gu; Chih-Hung Lee; Erol K. Bayburt; Jeffery McKie; Karen M. Alexander; Kathy L. Kohlhaas; Carol T. Wismer; Joe Mikusa; Michael F. Jarvis; Elizabeth A. Kowaluk; Shripad S. Bhagwat


Bioorganic & Medicinal Chemistry | 2007

4-amino-5-aryl-6-arylethynylpyrimidines : Structure-activity relationships of non-nucleoside adenosine kinase inhibitors

Mark A. Matulenko; Ernest S. Paight; Robin R. Frey; Arthur Gomtsyan; Meiqun Jiang; Chih-Hung Lee; Andrew O. Stewart; Haixia Yu; Kathy L. Kohlhaas; Karen M. Alexander; Steve McGaraughty; Joseph P. Mikusa; Kennan C. Marsh; Steven W. Muchmore; Clarissa L. Jakob; Elizabeth A. Kowaluk; Michael F. Jarvis; Shripad S. Bhagwat

Collaboration


Dive into the Karen M. Alexander's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Mark A. Matulenko

University of Wisconsin-Madison

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge